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Glomerular platelet-activating factor levels and origin in experimental
glomerulonephritis. The content of platelet activating factor (PAF) in
glomeruli isolated from rats with nephrotoxic serum glomerulonephritis
(NSGN) was quantified at various stages of the disease and the role of
complement, platelets and neutrophils in mediating changes in glomer-
ular PAF levels was evaluated. PAF content was assessed following
extraction, isolation and quantification of this alkyl ether lipid using a
bioassay based on [3H]-serotonin release from labelled rabbit platelets.
Following induction of NSGN using proteinuric doses of rabbit immune
serum raised against rat glomerular basement membrane, enhanced
glomerular PAF levels were observed at 3 hours, 24 hours and on day
15 following induction of the disease. In complement depleted rats and
at three hours following induction of NSGN, glomerular PAF levels
were significantly lower than in complement replete controls studied in
parallel. At the same time point of the disease, platelet depleted rats
with NSGN demonstrated significantly lower glomerular PAF levels
than parallel controls, whereas in neutrophil depleted rats glomerular
PAF levels were no different than controls. These observations indicate
that in infiltrative and complement dependent forms of glomerular
immune injury, glomerular PAF levels are increased via a complement
mediated mechanism. Infiltrating platelets, but not neutrophils, par-
tially account for the enhanced glomerular PAF levels. The observa-
tions are of potential importance in the pathophysiology of glomerulo-
nephritis.
The renal glomerulus and its various cell types have been
demonstrated to synthesize compounds with autacoid and
proinflammatory effects [1, 2]. The spectrum of proinflamma-
tory compounds of glomerular origin has recently expanded to
include the alkyl ether glycerophospholipids, including 1-0-
alkyl-2-acetyl-sn-glycero-3-phosphocholine, which is structur-
ally identical with platelet activating factor (PAF). This com-
pound can induce platelet and neutrophil aggregation and
chemotaxis, vasodilation and increased vascular permeability
and stimulation of eicosanoid production [3]. We have demon-
strated that PAF can be both synthesized and degraded in
isolated glomeruli [4] and in mesangial cells [5], the latter being
also capable of de novo synthesis of PAF precursors [6]. Recent
observations indicate that PAF receptor antagonism amelio-
rates glomerular inflammation in rabbit nephrotoxic serum
nephritis [71 as well as the glomerular inflammatory injury
Received for publication December 21, 1987
and in revised form August 18, 1989
Accepted for publication August 23, 1989
© 1990 by the International Society of Nephrology
induced by in situ formation of immune complexes in the rat
kidney with experimental passive reverse Arthus reaction [8].
The present study was undertaken to assess the levels and
cellular sources of glomerular PAF in glomeruli isolated from
rats with nephrotoxic serum glomerulonephritis (NSGN), an
infiltrative and complement dependent model of glomerular
immune injury. The role of complement system in mediating
changes in glomerular PAF levels was also assessed.
Methods
Induction of nephrotoxic serum glomerulonephritis (NSGN)
NSGN was induced in male Sprague-Dawley rats, weighing
250 to 300 g, by a single intravenous injection of proteinuric
doses of rabbit immune serum raised against particulate rat
glomerular basement membrane (GBM) as previously described
[9]. The immunoglobulin concentration of the immune serum
employed was determined by the immunodiffusion method of
Mancini, Carbonassa and Hermans [10] using goat anti-rabbit
IgG (Cappel Laboratories, Cochranville, Pennsylvania, USA)
and rabbit IgG (Sigma Chemical Company, St. Louis, Missouri,
USA). In all experiments, a single dose of immunoglobulin was
given (100 to 110 p.g/g of rat body wt), capable of inducing
proteinuria in the range of 150 to 250 mg of protein in 18- to
20-hour urine collection.
The following groups of animals were studied: a) rats with
NSGN studied at 3 hours, 24 hours and 15 days (N 4 to 6 for
each time point) following administration of anti-GBM immu-
noglobulin. Controls for each time point received identical
amounts of rabbit non-immune serum.
b) A group with NSGN underwent complement depletion (N
= 4) using cobra venom factor (CVF) (Sigma Chemical Co.)
purified by ion exchange and gel filtration chromatography [11]
and given intraperitoneally within a 24 hour interval and in three
divided doses (10 U/lOO g body wt) prior to administration of
anti-GBM immune serum. Complement depletion was docu-
mented in serum samples by a hemolysis inhibition assay
(CH5O) using antibody-sensitized sheep erythrocytes. In this
complement depleted group, studies were performed at three
hours following administration of the anti-GBM serum and
results were compared to the complement replete group of rats
with NSGN studied at three hours. Controls received CVF
alone.
c) A group with NSGN underwent platelet depletion (N 5)
prior to administration of anti-GBM immunoglobulin by a single
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Table 1. Experiments demonstrating PAF degradation to lyso-PAF by glomeruli isolated from rats with NSGN (24 hr) and controls
Experimental 3H-PAF
groups cpm
Glom. prot.
mg
lyso-PAF
cpm
pg lyso-PAF
mg/mg prot Mean SE
NSGN
#1
#2
#3
#4
Control
#1
#2
#3
#4
95040
95040
97002
102807
89156
70667
97404
97404
1.37
1.12
0.90
1.84
1.29
1.25
1.52
1.47
23120
25540
12320
23600
17060
10520
23120
24340
218
295
177
166
171
110
197
214
214 25
173 19
Glomeruli were incubated with 100 nCi of 3H-PAF and incubated for 20 mm at ambient temperature, Lipids were extracted and a portion was
analyzed by TLC. Product formation was expressed as pg lyso-PAF per mg glomerular protein, calculated on the basis of 3H-PAF specific activity.
intraperitoneal injection of rabbit anti-rat platelet immune se-
rum (source: Dr. K. Johnson, Department of Pathology, Uni-
versity of Michigan, Ann Arbor, Michigan, USA). Platelet
depletion was documented by assessing the absolute platelet
counts in peripheral blood samples using an automated hema-
tology analyzer; studies in this group were performed at three
hours following induction of NSGN and were confined to
animals in which the peripheral blood platelet count was less
that 10,000/mm3. Controls received non-immune rabbit serum.
d) A group with NSGN underwent neutrophil depletion (N =
4) by a single intrapentoneal injection of rabbit anti-rat poly-
morphonuclear leukocyte (PMN) immune serum (Accurate
Chemical Co., Westbury, Massachusetts, USA) given 18 to 20
hours prior to induction of NSGN. PMN depletion was docu-
mented by assessing absolute PMN counts in peripheral blood
using an automated hematology analyzer. Studies were per-
formed at three hours following induction of NSGN and were
confined to animals in which peripheral PMN counts of less
than 200 PMNs/mm3 were attained. Glomerular lesions were
assessed by light and immunofluorescence microscopy. Gb-
merular neutrophil infiltration was assessed by counting the
number of neutrophils in 20 glomeruli in renal cortical sections
obtained by sacrifice and stained by Eosin-Hematoxylin. Gb-
merular complement (C3) deposition was assessed by staining
for rat C3 using FTIC-conjugated goat anti-rat C3 immunoglob-
ulin (Cappel).
Biochemical studies
These studies assessed the content of PAF in glomeruli
isolated from the various groups of animals described above. In
a first step, we performed a number of experiments in order to
assess the metabolism of PAF by glomeruli isolated from rats
with NSGN at 24 hours following injection of the anti-GBM
immune serum (N = 4) and from control rats (receiving non-
immune rabbit serum) (N = 4). Glomerular incubations were
performed in RPMI medium-l640 (Gibco Laboratories, Grand
Island, New York, USA) with 100 nCi of l-0-[3H]-octadecyl-
2-acetyl-glycerophosphocholine ([3H1-PAF, specific activity 80
Ci/mmol, New England Nuclear, Boston Massachusetts, USA)
for 20 minutes at ambient temperature. Lipids were subse-
quently extracted from the glomerular suspensions by the
method of Bligh and Dyer, and products were analyzed by thin
layer chromatography using silica plates (10 x 10 cm, LHPK,
200 jsM; Whatman, Clifton, New Jersey, USA) and a solvent
system consisting of chloroform/methanol/water/glacial acetic
acid (50:25:4:8, vol/vol). Product formation was expressed as pg
of lyso PAF, calculated on the basis of specific activity of the
substrate ([3H]-PAF) per mg glomerular protein. Results are
shown on Table 1 and demonstrate substantial PAF degradation
to its inactive compound lyso-PAF as we and others have
previously described [4]. In view of the significant extent of
PAF degradation observed, we reasoned that changes in gb-
merular PAF levels occurring as a result of immune injury could
be significantly underestimated due to an apparent PAF enzy-
mic hydrolysis (deacetylation) which may occur during glomer-
ular isolation, a procedure which involves a 30 to 45 minute
time period. Therefore, we performed two types of measure-
ments: At the various time points of study (3 hours, 24 hours,
day 15), glomerular lipids were extracted immediately following
glomerular isolation and according to the procedure described
by Bligh and Dyer [12]. Briefly, glomeruli isolated by differen-
tial sieving [9] were suspended in 2 ml of RPMI medium 1640 in
polypropylene tubes at ambient temperature (23°C) and
"spiked" with approximately 3000 cpm of [3H] PAF standard in
order to calculate recoveries of this compound. Two ml of
potassium chloride 2 M/EDTA 0.5 M were subsequently added
followed by 5 ml of acidified (2% acetic acid) methanol.
Supernatants were further extracted three times with 4 ml of
chloroform and the chloroform-rich phases were pooled and
dried under nitrogen. Glomerular lipid extracts were subse-
quently dissolved in 300 d of chboroform:pyridine (3:1) and
were acetylated in the presence of acetic anhydride, 30 .d, and
of 4-N-dimethyl amino-pyridine, 2 mg, for 18 hours at ambient
temperature [131. Acetylated lipid extracts were subsequently
loaded on silica preparatory columns (SepPak, Waters Associ-
ates) which were pre-washed with chboroform:methanol (3:1).
Columns were sequentially eluted with 5 ml of chloroform:
methanol (1:1), 10 ml of methanol and 5 ml of methanol:water
(3:1). PAF was recovered in the last eluate which was dried
under vacuum and reconstituted in 300 s1 of sodium chloride
0.15 M/bovine serum albumin (BSA) 0.35% to be used for
quantification by the [3H] serotonin release assay. As chemical
acetylation may completely acetylate all lyso-PAF to PAF,
including the amount of lyso-PAF which had been produced in
vivo and prior to initiation of the glomerular isolation proce-
dure, this approach may not reflect PAF levels biologically
generated in vivo. Moreover, lyso-PAF cannot be regarded as a
sole index of PAF generation as it may also originate from
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glomerular alkyl acyl phosphatidyicholine following activation
of phospholipase A2. Therefore, glomerular PAF content in the
various experimental groups was also determined without prior
acetylation of lipid extracts. In these measurements glomerular
isolations and lipid extractions were performed at 4°C, a tem-
perature at which the activity of glomerular acetyl hydrolase
has been shown to be significantly inhibited [5J.
To quantify PAF content in glomerular lipid extracts, the [3H]
serotonin release assay was used and employed fresh rabbit
platelets labelled with [3H] serotonin and prepared from rabbit
platelet-rich plasma as previously described [14]. Labelled
platelets were suspended in tris-Tyrode's buffer containing
BSA 0.25% and consisting of KC1 2.6 X iO M, NaCl 1.37 x
101 M, tris(hydroxy-methyl-aminomethane) 1 x 10 M and
glucose 0.1%, pH 7.4. The suspension contained 1.25 x 106
platelets per d. To perform the assay, in 400 .d of tris-
Tyrode's/BSA supplemented with CaCl2 6 H20 1.3 x l0 M and
MgCl2 6 H20 1 x l0— M and containing indomethacin 1 x i0
M, creatinine phosphate 312.5 /Lg/ml and creatinine phosphoki-
nase 152.5 tg/ml, a defined volume (50 d) of glomeruli-derived
PAF extract was added followed by 100 pi of a [3H] serotonin-
labelled platelet suspension. The mixture was allowed to incu-
bate at 37° for three minutes and the reaction was stopped by 50
d formaldehyde 0.5 M, followed by centrifugation at 12000 g for
three minutes. Duplicate 100 jd aliquots of the supernate were
counted in a liquid scintillation counter (LKB WalIac, 1217
Rackbeta, Bromma, Sweden). Results were obtained on the
basis of a standard curve using PAF standard (range 0.1 ng to 1
ng). To construct the curve, the in of (dpm sample/dpm 100%
lysis-dpm sample) was plotted against known amounts of PAF
standard. One hundred percent platelet lysis was obtained by
the addition of 2.5% Triton X. The (dpm sample) and (dpm
100% lysis) values were corrected for background [3H] seroto-
nm radioactivity "noise" determined in samples containing
vehicle (tris-Tyrode's) only.
Glomerular PAF levels were expressed as mean SE values.
Statistical comparisons employed the Student's I-test for un-
paired observations. As the use of bioassay may be associated
with considerable interassay variation, PAF content in a num-
ber of glomeruiar extracts from different experimental groups
were determined in the same assay. For samples assayed in
different bioassays the interassay coefficient of variation was
determined. For animals receiving nonimmune serum and stud-
ied in parallel with either the various time groups or the
complement depleted groups or the neutrophile/platelet de-
pleted groups, the glomerular PAF content averaged 3.0 0.5,
3.76 1.0 and 2.59 0.5, respectively. The coefficient of
variation of these values was 19%.
Results
Figure 1 demonstrates the glomerular PAF levels in rats with
nephrotoxic serum glomerulonephritis at various time points
following administration of anti-GBM serum. Increased PAF
content (pmol/mg glomerular protein) was obtained at all time
points of study following induction of NSGN; namely at 3 hours
(25.1 2.7, N = 4), 24 hours (19.8 1.8, N = 4) and on day 15
(13.9 1.8, N = 4). PAF levels measured in glomeruli isolated
from rats treated with non-immune rabbit serum and sacrificed
at the same time points were 3.0 0.5 pmol/mg glomerular
protein (N = 10, values combined) and this value was signifi-
Fig. 1. Glomerular PAF content at 3 hr, 24 hr and on day 15 following
administration of a single proteinuric dose of anti-GBM immune serum.
(x), P < 0.001 compared to control group receiving non-immune serum.
NSGN: Nephrotic serum glomerulonephritis.
Fig. 2. Effect of complement depletion on glomerular PAF Content at
3 hr following induction of NSGN. PAF content in the decomplemented
group with NSGN (Group III) was lower compared to the complement
replete group with NSGN (Group II; * P < 0,001). PAF content in the
group receiving cobra venum factor alone (Group IV) was higher
compared to controls receiving non-immune serum (Group I; ** P <
0.01).
cantly lower (P < 0.001) compared to values obtained at 3
hours, 24 hours and on day 15. PAF content values obtained
using chemical acetylation of glomerular lipid extracts were
higher (47.2 8.6 at 3 hr; 60 12 at 24 hr and 73 8 on day 15)
compared to those obtained in non-acetylated glomerular lipid
extracts.
Figure 2 demonstrates the effects of complement depletion on
glomerular PAF levels in NSGN. In the complement depleted
group of rats studied at 3 hours (Group III), glomerular PAF
levels were significantly lower compared to the complement
replete three-hour group with NSGN studied in parallel (Group
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Fig. 3. Effect of neutrophile and platelet depletion on gloinerular PAF
content at 3 hr following induction of NSGN. Shown are PAF levels in:
I: Non-immune serum controls. II: NSGN at 3 hours following admin-
istration of anti-GBM serum. III: NSGN at 3 hours in a neutrophile
depleted group. IV: NSGN at 3 hours in a platelet depleted group. <
0.01. Group IV compared to Group II. Extent of glomerular neutrophile
infiltration (PMN/GL) in indicated in the rectangle.
II; 9.3 1.3, N = 4, compared to 32.9 5.4, N = 6 pmol/mg
protein, P < 0.001). In the complement depleted group (Group
III), glomerular PAF levels remained higher compared to
controls receiving non-immune serum and studied in parallel
(Group I; 9.3 1.3, N = 4, compared to 3.8 1.0 pmol/mg
protein, P < 0.001). Control rats receiving CVF alone (Group
IV) also had higher glomerular PAF levels compared to those
receiving non-immune rabbit serum (7.6 0.4, N = 3, com-
pared to 3.8 1.0 pmol/mg glomerular protein, P < 0.001).
In Figure 3, the effects of platelet depletion and PMN
depletion on glomerular PAF levels are shown. In the p4telet
depleted group of rats with NSGN studied at 3 hours (Group
IV), glomerular PAF levels were 13.9 1.8 pmollmg glomerular
protein (N 5), and this value was significantly lower (P <
0.01) compared to the platelet replete group studied at 3 hours
(Group II) (25.1 2.7 pmol/mg glomerular protein, N = 4). In
the neutrophile depleted group (Group III), glomerular PMN
infiltration was abolished (0 to 1 PMN/glomerulus). In this
group, glomerular PAF levels were not significantly different
from the neutrophil replete group studied at 3 hours following
induction of NSGN (Group II; 18.9 2.5, N = 4, compared to
25.1 2.7 pmollmg glomerular protein).
Discussion
Investigative work on the synthesis and role of alkyl ether
glycerophospholipids has recently involved the mammalian
kidney [15, 16]. We have confirmed previous observations [17]
that the rat glomerulus and mesangial cells can synthesize
1-0-alkyl-2-acetyl-sn-glycero-phosphocholine (PAF) via an
acetyl transferase as well as via a CDP choline phosphotrans-
ferase utilizing 1-0-alkyl-2-lyso-glycerophosphocholine or 1-
0-alkyl-2-acetyl-glycerol as substrates [4, 5]. Moreover, we
have demonstrated a significant degree of PAF enzymatic
degradation in glomerular tissue and in mesangial cells to its
biologically-inactive lyso-PAF compound [4]. Recent observa-
tions indicate that in glomerular immune injury induced by
anti-GBM antibody [7] or by in situ glomerular immune com-
plex formation [8], PAF apparently mediates pathophysiologic
perturbations and changes in glomerular permeability. It was
also demonstrated that cultured glomerular mesangial cells
release PAF and eicosanoids in response to IgG binding via the
fc receptor [18]. In the isolated perfused kidney platelet acti-
vating factor (s-PAF) increases glomerular permeability without
an effect on electrostatic barriers of the capillary wall [19]. In an
attempt to quantify glomerular PAF levels in immunologically
injured glomeruli, this study employed a well established bio-
assay, based on the ability of this alkyl-ether lipid to induce [3H]
serotonin release from freshly harvested and [3H] serotonin-
labelled rabbit platelets. Our experiments on glomerular metab-
olism of PAF indicate substantial acetyl hydrolase activity
(Table 1). In view of the extent of PAF degradation observed in
glomerular preparations, we initially performed chemical acet-
ylation of glomeruli-derived lipid extracts in order to convert all
lyso-PAF generated during glomerular isolation to bioassayable
PAF. The results indicated enhanced glomerular PAF content
at 3 hours, 24 hours and on day 15 following administration of
a single proteinuric dose of anti-GBM immune serum. How-
ever, since amounts of PAF obtained following chemical acet-
ylation of lyso-PAF may not reflect biologically synthesized
PAF in vivo and because lyso-PAF is not necessarily an index
of tissue PAF generation as it may also originate from alkyl acyl
glycerophosphocholine following phospholipase A2 activation,
we performed measurements of bioassayable PAF lipid extracts
obtained following glomerular isolation at 4°C to minimize the
activity of acetyl hydrolase. As demonstrated in Figure 1,
enhanced glomerular PAF content was found in immunologi-
cally injured glomeruli at the three time points of study. Several
sources of PAF can be implicated in this model of glomerular
injury. Blood-born platelets and neutrophils which are invari-
able present in glomeruli of rats with NSGN can account for the
enhanced glomerular PAF content, since both cell types can
synthesize PAF in response to various stimuli [20]. The platelet
and neutrophil depletion studies indicate that platelets, but not
neutrophils, partially account for the increased glomerular PAF
levels observed at 3 hours following induction of NSGN (Fig.
3). The complement depletion studies indicate that the comple-
ment system also mediates the increments in glomerular PAF
levels (Fig. 2). In complement-dependent forms of glomerular
injury, such as NSGN, activation of complement components
in glomeruli could mediate PAF synthesis by glomerular cells.
Indirect evidence that systemic activation of the complement
system can enhance glomerular PAF levels can be derived from
the observations that in rats which received intraperitoneal
injections of purified CVF (cobra C3b), glomerular PAF levels
were increased compared to the control group of rats which
received non-immune serum (Fig. 2). Moreover, in a prelimi-
nary study, we have demonstrated that anaphylatoxin C3a can
stimulate the activity of acetyl CoA: 1-0-alkyl-2-lyso-glycero-
phosphocholine acetyltransferase which acetylates the precur-
sor lyso-PAF to PAF [21]. Endogenous glomerular cells, includ-
ing endothelial, mesangial and the recently identified Ia-bearing
resident macrophages, the number of which increases in neph-
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rotoxic serum nephritis [22], could also be potential sources of
enhanced PAP synthesis in immunologically injured glomeruli.
Vascular endothelial cells in culture also synthesize PAF 123] as
do glomerular mesangial cells in response to defined immuno-
logic stimuli [18].
Whether reflecting an increase in PAF synthesis by glomer-
ular cells or an increase in the number of cells (that is, platelets)
capable of synthesizing PAF in the immunologically injured
glomerulus, increments in PAF levels can be of potential
pathophysiologic significance in glomerular immune injury. In
this regard, of relevance are the recent observations that
administration of exogenous PAF increases the permeability of
the glomerular basement membrane and reduces GFR by af-
fecting primarily the ultrafiltration coefficient [24]. This deter-
minant of GFR can be partially modulated by the contractile
state of mesangial cells which exhibit contractile responses
when exposed to PAF [25]. Moreover, PAF may induce loss of
anionic charges in glomerular basement membrane [26], an
effect which could mediate proteinuria in glomerular immune
injury. Finally, evidence for a regulatory relationship between
glomerular PAF and TxA2 synthesis has recently been demon-
strated in NSGN. Specifically, PAP receptor blockade amelio-
rates enhanced glomerular TxA2 synthesis and proteinuria, and
has a beneficial effect on glomerular histopathology [27].
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